Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss

The arrival of more effective obesity medications has made it possible to investigate what treatment achieves beyond a change on the scale, Daniel J. Drucker, MD, says in an interview with Patient Care Online. In this segment, the University of Toronto professor explains why the Endocrine Society issued its September 9, 2026, scientific statement and what its research agenda means for primary care.¹

Drucker says the statement emerged as the Society expanded its obesity resources and as pharmacotherapy changed the questions researchers could credibly ask. Its six priority areas encompass body fat regulation, variation in treatment response, targets beyond percentage weight loss, the phases of weight reduction and maintenance, health outcomes, and medication safety. The authors describe gaps in evidence; the statement is not a treatment guideline.¹

Asked for a practical takeaway, Drucker turns to the patient's reason for seeking care. Someone with severe obesity, obstructive sleep apnea, and osteoarthritis may prioritize breathing, pain, and mobility alongside substantial weight reduction. Another patient with a lower BMI may be chiefly concerned about cardiovascular disease. In each case, he argues, clinicians need to identify the outcome that matters to the patient before deciding how to measure success. His examples illustrate different priorities, not established dose or weight-loss thresholds for preventing cardiovascular events.

The SELECT trial shows why disease outcomes merit separate attention. Among 17 604 adults with overweight or obesity, established cardiovascular disease, and no diabetes, major adverse cardiovascular events occurred in 6.5% assigned to semaglutide 2.4 mg and 8.0% assigned to placebo over a mean 39.8 months (hazard ratio, 0.80; 95% CI, 0.72-0.90).² The finding applies to the studied population and regimen; it does not establish equivalent protection at lower doses.

References

1. Jastreboff AM, et al. Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Endocr Rev. Published September 9, 2026. doi:10.1210/endrev/bnag025.
2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. doi:10.1056/NEJMoa2307563